Policy Perspective
COGR Testimony at NIH Hearings on March-in Rights
NIH has denied the request from Essential Inventions, Inc. to exercise march-in rights under The Bayh-Dole Act in connection with the pricing of Norvir, marketed by Abbott Laboratories for the treatment of patients with HIV/AIDS. The decision and related materials are available online.
Costing Issues
COGR provides an in-depth analysis of how universities address federal requirements for effort reporting related to compensation on federally funded research awards. Triggered by recent audit findings and heightened oversight, the paper explores the relevant federal guidance—principally OMB Circular A-21 and A-110—and highlights the inherent challenges universities face in accurately tracking and
Notification Letter for 45 CFR 46.118 Determinations for NSF Awards
COGR has been working with NSF staff to develop
151904
The February 2012 COGR Meeting Report details significant developments and ongoing issues in federal research policy, especially those affecting university research administration. A major focus is the Office of Management and Budget’s (OMB) grants reform initiative, as outlined in the Advance Notice of Proposed Guidance (ANPG), which proposes consolidating multiple OMB circulars governing grants,
151875
The October 2011 meeting report of the Council on Governmental Relations (COGR) provides a detailed overview of current federal policies, regulatory reforms, and compliance issues affecting research universities and other research institutions. Key topics discussed include updates on federal costing policies, such as the progress of the A-21 Task Force in reviewing effort reporting and F&A (fa
151849
The June 2011 COGR Meeting Report provides a comprehensive overview of key policy, regulatory, and operational issues impacting the administration of federally funded research at U.S. universities and research institutions. The report details discussions with Commerce/BIS officials on evolving export control regulations and compliance expectations—especially around deemed exports and the I-129 cer
